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1. Introduction 
Bisphosphonates (BPs) play a key role in the treatment of both primary and secondary 
osteoporosis on account of their effect on the calcium metabolism in the human body. The 
administering of BPs reduces the frequency of fractures of the spine, the neck of the femur 
and the wrist. They also promote bone mass growth in the whole skeleton. In addition, they 
improve the quality of life of treated patients significantly (Almazrooa & Woo, 2009; Watts 
& Diab, 2010).  
However, during the course of treatment with bisphosphonates it is of importance to bear in 
mind the possible development of a specific complication, namely osteonecrosis of the jaw. 
It should be noted that no bisphosphonate-related necrosis is observed in other bones.  
Since 2003 when the first cases of osteonecrosis of the jaw following BP administration were 
described (Marx, 2003), more references to BPs Bisphosphonate–Related Osteonecrosis of 
the Jaw, i.e. BRONJ, have appeared in the literature, encompassing new and more numerous 
groups of patients (Durie et al., 2005; Kos et al., 2010; Otto et al., 2011; Ruggiero et al., 2004). 
BRONJ was initially observed in patients receiving BPs for malignant tumours, bone 
metastases (most frequently from breast, prostate or lung cancer), and in cases of multiple 
myeloma (Wang et al., 2007). BPs such as pamidronate and zoledronate were applied 
intravenously and doses of the medication exceeded many times over the dose used in 
osteoporosis. Recently, BRONJ has likewise been confirmed in patients with osteoporosis 
who had received oral alendronate, and in earlier years - etidronate (Magremanne, 2008; 
Palaska et al., 2009; Watts & Diab, 2010).  
BRONJ manifests itself as a necrotically changed, exposed bone with a depleted mucous 
membrane and often accompanying by inflammation (Peters et al., 1993). It frequently 
follows a tooth extraction. It occurs more commonly in the mandible than in the maxilla 
(Kos et al., 2010; Ruggiero et al., 2004). 
Osteonecrosis of the jaw can also be triggered by other factors than the administering of BPs 
(Almazrooa & Woo, 2009). It occurs after: radiation therapy of the facial area, trauma 
(osteotomy of the jaw bone or during intubation), viral infection (Herpes zoster or HIV), 
fungal infection with Aspergillus, circulatory insufficiency, local application of chemical 
agents in dental treatment, inhaling cocaine, and osteomyelitis. Also described is the 
idiopathic exposure of the lingual surface of the mandibular base in its posterior section in 
the area of the protruding mylohyoid ridge covered with thin mucous membrane and 
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poorly vascularised as a physiological result of trauma of the mucosa membrane in 
generally healthy individuals. BRONJ most frequently appears in this region. Osteonecrosis 
is also encountered in cases of long-term steroid use, but usually it affects the femur 
(Almazrooa & Woo, 2009). 
Diagnosis of BRONJ can be made in case of bone exposure lasting longer than eight weeks, 
with no previous history of radiation therapy of the facial region (Almazrooa & Woo, 2009; 
Ruggiero et al., 2006). 
2. Clinical and radiologic profile 
Necrosis of the jaw bone in patients treated with BPs can remain asymptomatic for many 
months or even years.  
 
 
 
Fig. 1. Redness of the oral mucosa and purulent fistulas of the lower gingiva 
The bone becomes exposed, and is sometimes accompanied by pain. The first symptoms 
before the emergence of a clinically developed image of necrosis include pain, tooth 
mobility, swelling and redness of the mucosa membrane, and ulceration (Figure 1). These 
symptoms can appear independently, but much more commonly they do occur after 
surgery on the alveolar ridge, mostly after tooth extraction. Since the post-extraction socket 
does not heal, subsequently pain sensation occurs, followed by inflammation of the 
surrounding tissue and bone necrosis. This leads to pathological fractures of the mandible, 
the appearance of skin (Figure 2) and gingival (Figure 1) fistulas or secondary inflammation 
of the maxillary sinus and oro-antral fistulas in the area of necrosis. Numbness of the skin of 
the lips and face may also be observed. In the initial period the exposed bone is smooth 
before later becoming rough and coarse. The sharp border of the bone can cause subsequent 
ulceration of the surrounding tissue exposed to the injury. The most frequent site of 
traumatic ulceration is the posterior-lateral part of the tongue adjacent to the sequestrum on 
the lingual surface of the mandibular body (Migliorati et al., 2005; Ruggiero et al., 2006). 
Initially radiological images show no significant changes (Figure 3). There may be a 
widening of the periodontal space around existing teeth, and later rarefaction of the bone as 
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in the case of bone inflammation, as well as loss of bone structure. Later, bone sequestra 
may develop, leading to pathological fractures (Figure 4) (Almazrooa & Woo, 2009; 
Ruggiero et al., 2006).  
 
 
Fig. 2. Skin fistula in course of BRONJ 
 
 
Fig. 3. Unobtrusive marginal osteolysis during the initial phase of BRONJ (arrow) 
Histopathological examination demonstrates typical images of chronic inflammation of the 
bone with fibrous granulation tissue with abundant, chronic partially purulent 
inflammatory infiltration and necrotically changed osseous trabeculae (Figures 5, 6 & 7) 
(Migliorati et al., 2005; Ruggiero et al., 2006; Panaś et al., 2010). 
Ruggiero et al. (2006) suggested a division of BRONJ into three degrees depending on the 
progress in the pathology: 
Degree 1: Exposure of bone without swelling or redness of the surrounding soft tissue (Figure 
1). No change in the radiological image. The exposure of the bone may be preceded by pain. 
Degree 2: Exposure of bone with inflammatory swelling of the soft tissue or with a 
secondary infection, the presence of pain and teeth mobility. Radiological images show 
necrotic changes in the bone that may resemble rarefaction of bone around the apices of the 
teeth (Figure 10), widening of the periodontal space. 
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Degree 3: Exposure of bone with accompanying pain, inflammatory swelling of the 
surrounding soft tissue or secondary infection that is difficult to control with antibiotic 
treatments. Appearance of gingival and skin fistulas in the region of bone sequestra or 
pathological fractures of the mandible, hypoesthesia of the lower lip, as well as secondary 
inflammation of the maxillary sinus, and oro-nasal fistula in the necrosis of the jaw. 
Radiograms show bone rarefaction, sequestra, and sometimes pathological fractures  
(Figure 4).  
 
 
 
 
Fig. 4. Pathological fracture in course of BRONJ of the right mandible body 
 
 
 
Fig. 5. Histopathological examination of BRONJ (H&E, x60) 
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Fig. 6. Histopathological examination of BRONJ (H&E, x120) 
 
 
Fig. 7. Histopathological examination of BRONJ (H&E, x140) 
3. Pathogenesis 
The pathogenesis of BRONJ is connected with the fact that BPs have a significant influence 
on the physiological process of bone tissue remodelling by hampering the effect of 
osteoclasts function, leading to their apoptosis and the inhibition of the differentiation of 
osteoclast precursor cells. BPs also inhibit angiogenesis by reducing the level of VEGF 
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(vascular endothelial growth factor) in the blood (Almazrooa et al., 2009; Marx, 2003; 
Ruggiero et al., 2004). Certain bisphosphonates (i.e. pamidronate) significantly reduce blood 
flow through the diploe, as shown by experimental research, and this may be the reason for 
the occurrence of ischaemic osteonecrosis (Choi et al., 2007). BPs tend to be deposited in the 
jaw bones because of their high metabolic rate. The greater metabolic rate is caused by the 
constant pressure on the bone, especially during chewing. Micro-cracking of the maxillary 
bone resulting from the physiological force of chewing requires repair, and the need for 
bone repair and remodelling increases in the case of surgical procedures, i.e. after tooth 
extraction, which in patients receiving BPs is hampered by the inhibition of key elements in 
this process (Migliorati et al., 2005). Reduced blood supply in the mandibular body in its 
posterior section on the lingual side explains the frequent appearance of BRONJ in this area.  
Risk factors  for the development of BRONJ (Table 1) include radiotherapy of the facial region, 
chemotherapy, the use of corticosteriods, diabetes and coagulopathies (Palaska et al., 2009; 
Ruggiero et al., 2006). The duration, type and method of BP treatment are also significant 
factors that determine the appearance of osteonecrosis. The longer the bisphosphonate is 
administered the greater the risk of BRONJ appearing. When administered intravenously, 
necrosis occurs 4.4 times more frequently compared to oral route of administration, and 
among intravenous medications it is most common with zoledronic acid (Almazrooa & 
Woo, 2009) . The average time for BRONJ to appear is 2 years for BPs administered 
intravenously among patients with neoplastic diseases, as compared with 4.6 years for oral 
therapy in cases of osteoporosis, with the minimum time being 3 years (Palaska et al., 2009). 
Tobacco smoking and excessive alcohol intake also favour the development of BRONJ.  
 
General risk factors Local risk factors
Concomitant therapies: corticosteroids, other 
immunosuppressants (eg methotrexate, 
thalidomide), chemotherapeutic agents (eg 
hormone antagonists) 
 
Systemic conditions affecting bone turover: 
immunocompromised patients, rheumatoid 
arthritis, poorly controlled diabetes 
 
Smoking 
 
Sociodemographic characteristics: extreme of 
age (over 6th decade), gender (females) 
Mandibular molar extractions 
(two thirds of BRONJ cases 
have been reported in the mandible) 
 
All dentoalveolar surgery 
 
Periodontitis/poor oral hygiene  
(the bacterial biofil present in periodontal 
disease is responsible for gingival 
inlammation and alveolar bone resorption; 
this pathology, together with the interactions 
between bacteria themselves and BPs can 
increase the possibility of BRONJ) 
 
Trauma related to dentures 
 
Thin mucosal coverage, lingual to lower 
molars and bony tori 
Table 1. Risk factors for developing BRONJ according to Malden et al. (2009) 
A particularly high risk factors for BRONJ development are the extraction of a tooth or any 
other surgery on the alveolar ridge as well as injury to the mucosa membrane by a denture 
plate and the occurrence of ulceration (Marx, 2007; Ruggiero et al., 2006). The bacterial 
environment of the oral cavity favours secondary superinfection with subsequent 
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inflammation. Aerobic bacteria strains predominate in bacteriological tests, including 
Streptococci sensitive to penicillin and clindamycin, but Actinomyces species and Eikenella 
corrodens are also quite often cultured (Block Veras et al., 2008; Panaś et al., 2010). In addition, 
bacterial products increase bone resorption and decrease rate of bone remodelling, when there 
is an increased need for remodelling of the bone after surgery performed on the alveolar ridge.  
4. Treatment  
Treatment of patients with BRONJ is difficult and challenging. The recommended therapy 
for first degree BRONJ cases is frequent rinsing of the oral cavity with an antiseptic solution, 
e.g. chlorhexidine, together with regular clinical check-ups of the oral cavity.  
In case of a second degree BRONJ one shall undergo antibacterial therapy involving a 
targeted antibiotic, together with analgesics and rinsing of the oral cavity.  
During the third degree BRONJ the surgical removal of necrotic bone is necessary. Targeted 
antibiotic therapy administered orally or intravenously is also advisable (Rizzoli et al., 2008), 
as is intensive rinsing of the oral cavity. In addition to the removal of bone sequestra, it is 
also often necessary to perform a partial resection of the mandible or maxilla (Kunchur et 
al., 2009; Ruggiero et al., 2006; Williamson, 2009). Moreover, some authors propose the 
application of hyperbaric oxygen therapy (Migliorati et al., 2005).  
Discontinuation of BPs therapy remains an issue of contention on account of their long half-
life time, i.e. approximately 10 years, after they become concentrated within the body 
skeleton (Dello Russo, 2007). Any decision to withdraw BPs due to the development of 
BRONJ should be made by consensus with the attending physician and dentist.  
Due to the long half life times of BPs in the bone, osteonecrosis recurs despite the 
introduction of the appropriate treatment (Watts & Diab, 2010).  
5. Prevention 
Because of the difficulties in treating BRONJ and the specificity of this chronic disease, 
prevention is of vital importance.  
Before BPs treatment is implemented, all patients should be referred for dental examination 
(Shane et al., 2006). It is important to achieve oral cavity assanation, so that no surgical 
procedures on the alveolar ridge will be necessary during the course of BPs treatment, 
which significantly increases the risk of the development of BRONJ. It will be necessary to 
extract those teeth that are not suitable for conservative or endodontic treatment, carry out 
conservative therapy on other teeth and also perform periodontal treatment. Teeth for 
which the prognosis for restoration is poor should be extracted. Other essential hygienic 
procedures and elective dento–alveolar surgery should be performed during this period. 
The introduction of bisphosphonates should take place 4 - 6 weeks after the dento–alveolar 
surgery, after suitable healing of the bone wound (Kunchur et al, 2009; Malden et al., 2009; 
Ruggiero et al., 2006).  
Prophylactic procedures in the oral cavity, consisting in the maintenance of good oral hygiene, 
control of caries, and conservative therapy, must continue for the entire period of BPs 
treatment. Patients using removable partial or complete dentures must be examined to identify 
any possible pressure of the denture base on the mucosa membrane of the oral cavity as well 
as the emergence of decubitus ulcers, especially in the lingual region of the lower prosthesis.  
Patients must be taught the necessity of regular dentist check-ups and maintaining perfect oral 
hygiene as well as the importance of refraining from smoking and alcohol drinking. Patients 
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should also be made aware of early manifestations of developing osteonecrosis, which should 
be reported immediately to a dentist; any pain sensations in the oral cavity, oedema or bone 
exposure, should be reported to the attending physician (Haumschild & Haumschild, 2010).  
During the course of BPs treatment surgical procedures involving teeth extractions should 
be avoided. If a tooth is not suitable for restoration crown of the tooth should be removed, 
but its roots should be left in place after endodontic treatment. However, significantly 
mobile teeth with periodontal abscess should be extracted. The timing and conditions of this 
procedure should be determined by the dental surgeon in consultation with the attending 
physician. Certain authors suggest that to minimise the risk of BRONJ, BPs treatment should 
be interrupted (“drug holidays”) prior to the planned surgical procedure and, if the need 
arises, BPs should be replaced with a different medication used for osteoporosis. Recently it 
has been postulated that the CTX test (the C–terminal Cross–Linking Telopeptide test) 
should be carried out beforehand. This test can identify a risk group of patients treated with 
BPs as a measure of the total rate of bone remodelling. A safe CTX value prior to the 
procedure is 150 pg/ml. The surgery should be carried out with an antibiotic prophylaxis, 
the most recommended being penicillin derivatives or metronidazole (Bahlous et al., 2009; 
Kunchur et al., 2009; Malden et al., 2009; Marx et al., 2007). 
Placement of dental implants in patients receiving intravenous BPs should be avoided 
(Ruggiero et al., 2006). However, some authors claim that oral route of BPs administration 
does not conflict with dental implant placement (Dello Russo et al., 2007). Nevertheless, in 
these cases, prophylactic antibiotic administration is obligatory and informed consent about 
an increased risk of implant failure should be provided. 
In view of the possible development of BRONJ with prolonged BPs treatment for 
osteoporosis, the option of BP withdrawal after 5 years should be considered, a fact which 
shall be decided by the attending physician. Prolonged BPs therapy of more than 5 years 
should be carefully considered for patients with a high risk of spinal fracture, e.g. those with 
very low BMD (bone mineral density) (Watts & Diab, 2010).  
Some authors claim that bone healing in patients who have been taking oral BPs for less 
than 3 years is expected to be uncomplicated (Marx et al., 2007). In this period, the 
accumulation of an oral BP in bone is slowed by its minimal gastrointestinal absorption 
(Dello Russo et al., 2007). Therefore, a serum CTX is not required prior to oral surgical 
procedures. However, if the patient relates a history of greater than 3 years of oral BP use or 
fewer than 3 years but with concomitant corticosteroid or chemotherapy use, a CTX test is 
highly recommended (Marx et al., 2007). 
6. Conclusion 
BRONJ complications during BPs treatment appear far more commonly among cancer patients 
who have received high doses of BPs intravenously. However, until now 200 cases of BRONJ 
have been observed in patients with osteoporosis (Rondon, 2009). Owing to an ageing 
population and the growing number of patients with osteoporosis, for whom BPs play a key 
role in their treatment, more attention should be paid to this problem as well as to learning the 
risk factors for the development of BRONJ. An important factor affecting the outcome of 
osteoporosis treatment is co-operation between the attending physician and the dentist. 
One example of the development of BRONJ following BP administration is the case of a 70-
year old female patient with osteoporosis who was treated with oral bisphosphonate 
(alendronate group) for 8 years. She reported periodic pain and bleeding in the posterior 
part of the lower gingiva under the denture base, where a small fistula was identified 
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together with redness of the mucosa membrane. A pantomographic X-ray revealed 
rarefaction of the bone of the mandibular body on the left side with a diameter of 3 
centimetres (Figure 8). Actinomyces naeslundi were cultured in the bacteriological test. With 
a targeted antibiotic prophylaxis (clindamycin) curettage was performed on inflamed 
granulation tissue with minor bone sequestra from the area of the bone rarefaction. 
Histopathological tests showed fibrous-granulation tissue with extensive partially purulent 
inflammatory infiltration and necrotically changed osseous trabeculae with adjacent 
colonies of Actinomyces. Two months before, BP was withdrawn and a preparation of 
calcium and vitamin D3 was prescribed instead. The pain resumed 8 months after the 
surgery and an X-ray showed an increase in rarefaction of the bone structure (Figure 9). An 
antibiotic was used once again and the bone was curetted. Nine months later pain and a 
purulent fistula appeared in the region of the endodontically treated upper premolar tooth 
25, together with a focus of the rarefaction of the bone structure on the X-ray (Figure 10), 
which was subsequently curetted. Histopathological test: osteomyelitis. The patient is 
currently in the course of another seven month follow-up without complications. CT does 
not show any new osteolytic lesions in the jaws (Figure 11). 
 
 
Fig. 8. Focal osteolysis of the left mandible body 
 
 
Fig. 9. Follow-up X-ray examination reveals progression of the bone resorption 
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Fig. 10. Osteolytic lesion in the periapical area of the tooth 25 
 
Fig. 11. Follow-up CT-scan confirming the existence of osteolytic lesions in the left mandible 
body and in the left maxilla. However, it does not reveal any new lesion 
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